NexImmune, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 32.34 million compared to USD 62.51 million a year ago. Basic loss per share from continuing operations was USD 30.82 compared to USD 64.95 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.44 USD | -0.72% | -0.58% | +54.95% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+54.95% | 4.72M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.61% | 22.28B | |
-11.90% | 22.41B | |
-5.43% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- NEXI Stock
- News NexImmune, Inc.
- NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023